Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics (CVE:ATE)


Share Price
$ 0.36
Change
0.015 (4.35 %)
Market Cap
$87.52 m
Proactive Investors - Run By Investors For Investors

Antibe Therapeutics

Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a $20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety and efficacy in the...

EPIC: ATE
Market: TSX-V:ATE
OTCMKTS:ATBPF
52-week High/Low: C$0.46 / C$0.24
Sector: Health Care, Equipment & Services
Market Cap: $87.52 m
Website: antibethera.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Antibe Therapeutics


Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use